Smith & Nephew plc Receives “Add” Rating from Numis Securities Ltd (SN.)
Smith & Nephew plc (LON:SN.)‘s stock had its “add” rating reaffirmed by investment analysts at Numis Securities Ltd in a note issued to investors on Friday, AmericanBankingNews.com reports. They currently have a GBX 870 ($14.08) target price on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Smith & Nephew plc in a research note to investors on Thursday. They now have a GBX 890 ($14.40) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note to investors on Tuesday. They now have a GBX 791 ($12.80) price target on the stock, up previously from GBX 740 ($11.97). Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of Smith & Nephew plc in a research note to investors on Friday, October 25th. They now have a GBX 650 ($10.52) price target on the stock. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of GBX 785 ($12.70).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.